Safety of Peripherally Infused Sympathomimetic Vasopressors in the Intensive Care Unit and Emergency Department.
- Published in:
- Annals of Pharmacotherapy, 2025, v. 59, n. 5, p. 397, doi. 10.1177/10600280241284796
- By:
- Publication type:
- Article
Works matching IS 10600280 AND DT 2025 AND VI 59 AND IP 5
Results: 11
1
2
Characterization of Ganciclovir Dosing for the Management of Cytomegalovirus in Solid Organ Transplant Recipients Receiving Sustained Low-Efficiency Dialysis.
- Published in:
- Annals of Pharmacotherapy, 2025, v. 59, n. 5, p. 406, doi. 10.1177/10600280241283966
- By:
- Publication type:
- Article
3
Transitions of Care Pharmacist Impact Following Hospitalization for Acute Myocardial Infarction.
- Published in:
- Annals of Pharmacotherapy, 2025, v. 59, n. 5, p. 439, doi. 10.1177/10600280241278791
- By:
- Publication type:
- Article
4
B-Cell Maturation Antigen-Directed Immunotherapies for the Treatment of Relapsed/Refractory Multiple Myeloma: A Review of the Literature and Implications for Clinical Practice.
- Published in:
- Annals of Pharmacotherapy, 2025, v. 59, n. 5, p. 463, doi. 10.1177/10600280241282115
- By:
- Publication type:
- Article
5
Detectable Concentrations With Inhaled Tobramycin in Critically Ill Infants and Children Following Implementation of Standardized Protocol.
- Published in:
- Annals of Pharmacotherapy, 2025, v. 59, n. 5, p. 430, doi. 10.1177/10600280241282433
- By:
- Publication type:
- Article
6
Inhaled Medications for Maintenance Therapy in Pediatric Noncystic Fibrosis Bronchiectasis.
- Published in:
- Annals of Pharmacotherapy, 2025, v. 59, n. 5, p. 446, doi. 10.1177/10600280241279602
- By:
- Publication type:
- Article
7
Exploring Safety in Gender-Affirming Hormonal Treatments: An Observational Study on Adverse Drug Events Using the Food and Drug Administration Adverse Event Reporting System Database.
- Published in:
- Annals of Pharmacotherapy, 2025, v. 59, n. 5, p. 491, doi. 10.1177/10600280241278913
- By:
- Publication type:
- Article
8
Engaging a New Treatment Paradigm: Elranatamab in Relapsed/Refractory Multiple Myeloma.
- Published in:
- Annals of Pharmacotherapy, 2025, v. 59, n. 5, p. 473, doi. 10.1177/10600280241281742
- By:
- Publication type:
- Article
9
Reply: "Exploring Safety in Gender-Affirming Hormonal Treatments: An Observational Study on Adverse Drug Events Using the Food and Drug Administration Adverse Event Reporting System Database".
- Published in:
- Annals of Pharmacotherapy, 2025, v. 59, n. 5, p. 493, doi. 10.1177/10600280241277860
- By:
- Publication type:
- Article
10
Incidence and Risk Factors of Hypomagnesemia in Patients With Bone Metastasis From Solid Malignancies Treated With Denosumab.
- Published in:
- Annals of Pharmacotherapy, 2025, v. 59, n. 5, p. 415, doi. 10.1177/10600280241277557
- By:
- Publication type:
- Article
11
Bypassing Prescribers and Pharmacists: Online Purchasing of Semaglutide and Tirzepatide "For Research Purposes".
- Published in:
- Annals of Pharmacotherapy, 2025, v. 59, n. 5, p. 485, doi. 10.1177/10600280241277551
- By:
- Publication type:
- Article